Return to search

Chord Therapeutics grabs $16m Series A

Chord Therapeutics, a Swiss developer of drugs for rare diseases, has raised $16 million in Series A financing.

Chord Therapeutics, a Swiss developer of drugs for rare diseases, has raised $16 million in Series A financing. The investor was Omega Funds. In conjunction with the financing, Omega Funds’ Managing Director Claudio Nessi and Principal Francesco Draetta will join Chord Therapeutics’ board.

Source: Press Release